GlassScriptPhysician profile
Holly E Caputy
NPI 1235491200
$7,132.98
in general payments reported to CMS, 2019-2025
23 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $191 · 2021: $237 · 2022: $734 · 2023: $1,944 · 2024: $645 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068 · Travel and Lodging: $1,303 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,285 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.93 |
| Travel and Lodging | $1,302.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,285.00 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,093.12 | 2019-2025 | Acuvue |
| Coopervision INC. | $2,003.68 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $667.49 | 2019-2021 | |
| Alcon Vision LLC | $444.44 | 2019-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $420.57 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $214.95 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $190.88 | 2019-2024 | |
| Lkc Technologies, INC. | $184.63 | 2023-2025 | |
| Abbvie INC. | $175.85 | 2022-2023 | Vuity, Lumigan |
| Novartis Pharmaceuticals Corporation | $130.19 | 2020-2023 | |
| Glaukos Corporation | $112.89 | 2022 | |
| Apellis Pharmaceuticals, INC. | $103.40 | 2024 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $75.29 | 2024-2025 | Xdemvy |
| Optovue, INC. | $59.55 | 2019-2020 | |
| Harrow Eye, LLC | $49.66 | 2024 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $45.05 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $39.97 | 2021 | |
| Biotissue Holdings INC. | $29.35 | 2025 | |
| Thea Pharma INC. | $23.49 | 2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $18.50 | 2022 | |
| Abb Con-Cise Optical Group LLC | $17.66 | 2019 | |
| Allergan, INC. | $17.39 | 2021 | |
| Shire North American Group INC | $14.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Caputy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.